dermatofibrosarcoma protuberans, atypical fibroxanthoma, and leiomyosarcoma.
Methotrexate is generally administered once weekly to patients, with doses ranging from 7.5 to 25 mg/week. At the doses typically used, this medication has an anti-inflammatory effect as it increases the levels of intracellular adenosine. When used at high doses in oncology, it has anti-metabolic effects on cells with a high mitotic activity. 2 Although safe and widely used in low doses, it is not free from side effects, which often lead patients to discontinuing the medication. 4 The side effects of MTX are mainly gastrointestinal intolerance and hepatotoxicity. Although rare, some severe manifestations have been reported such as cytopenia, mucocutaneous toxicity, pneumonitis, neurotoxicity and nephropathy. 5 The presence of oral mucositis, cutaneous ulcerations and pancytopenia (which may be followed by sepsis) suggest severe acute toxicity, since the drug inhibits rapid cell turnover. 2 Pancytopenia presents within the first 10 days of treatment.
It is dose dependent but occasionally it may be idiosyncratic. Mucositis usually occurs within the first 7 days of administration, prior to the onset of pancytopenia, as the accumulation of MTX is higher in mucosal epithelial cells than in the bone marrow stem cells.
2,4,5
Cutaneous involvement usually appears with mucositis. Its mechanism of action has been associated with direct drug toxicity in epithelial cells 2 , as seen in our patient. Histologically, this toxicity is evidenced by severe keratinocyte necrosis. how much of a medication should be given. 
